hailshadow-istockphoto-com

Hailshadow / iStockphoto.com

17 September 2018Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

The European Patent Office (EPO) has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières (MSF).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More on this story

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Gilead to launch generic versions of its hep C drugs

26 September 2018 Gilead is set to produce cheaper authorised generic versions of its branded hepatitis C treatments from 2019.

Appeal filed against EPO sofosbuvir patent decision

10 December 2018 Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility